Column | A blood test for 50-plus cancers? One survivor is glad he took it. - The Washington Post

Column | A blood test for 50-plus cancers? One survivor is glad he took it.  The Washington Post5 doctors weigh in on the promise, limitations of Grail’s multicancer test  MedTech DiveAs FDA sidesteps the question of Galleri’s clinical benefit, NCI’s Letai has “some concerns”  The Cancer LetterIs GRAIL (GRAL) Still Below Fair Value As Fresh Galleri Data Nears?  Simply Wall StreetViewpoint: RFK Jr.’s stacked FDA advisory council endorses multicancer screening test from ethically- questionable company that would increase false positives and waste billions of dollars  Genetic Literacy Project